Dilip Shanghvi Net Worth

Dilip Shanghvi was born on October 01, 1955 in Amreli, Gujarat, India, India. He founded Sun Pharmaceutical Industries and serves as managing director. The son of a pharmaceuticals distributor, he borrowed $200 from his father to start Sun in 1983 to make psychiatric drugs. The company is the world's fifth largest generics maker and India's most valuable pharma outfit with 2016 revenues of $4.1 billion He grew Sun through a series of shrewd acquisitions, the biggest of which was the purchase of scandal-tainted rival Ranbaxy Laboratories for $4 billion in 2014. His fortune has declined two years in a row as Sun's shares fell after the U.S. Food and Drug Administration observed manufacturing lapses at one of its biggest factories in India.
Dilip Shanghvi is a member of Health care

Age, Biography and Wiki

Birth Day October 01, 1955
Birth Place Amreli, Gujarat, India, India
Birth Sign Scorpio
Residence Mumbai, India
Alma mater University of Calcutta
Occupation Founder and MD of Sun Pharmaceuticals
Spouse(s) Vibha Sanghvi
Children 2

💰 Net worth: $13.7 Billion (2022)

2009 $3 Billion
2010 $4.6 Billion
2011 $6.1 Billion
2012 $7.4 Billion
2013 $9.4 Billion
2014 $12.8 Billion
2015 $20 Billion
2016 $16.7 Billion
2017 $13.7 Billion
2018 $11.44 Billion

Some Dilip Shanghvi images

Famous Quotes:

Our story is all about incremental growth. We"re not looking for big leaps; we prefer small jumps.



Shanghvi started Sun Pharmaceutical Industries with capital of ₹10,000 in 1982 at Vapi, with one psychiatry drug and a partner, Pradeep Ghosh. In 1997, Sun acquired Caraco Pharma, a loss-making American company, with the aim of expanding Sun's reach in the United States. Sun also acquired Israel's Taro Pharma in 2007. Shanghvi stepped down as chairman and CEO in 2012 and chose Israel Makov, formerly CEO of Teva Pharmaceuticals, as his successor; Shangvi became managing Director. In April 2014 Sun, Ranbaxy, and Daiichi Sankyo (the majority shareholder in Ranbaxy) agreed that Sun would acquire all outstanding shares of Ranbaxy for $3.2B in Sun stock and that Sun would take on $800M in Ranbaxy debt; the deal closed in March 2015 and made Sun the largest drug company in India and the fifth largest in the world, and made Daiichi the second largest shareholder in Sun.


As of August 2014, he had a net worth of $17.2 billion.